financetom
Business
financetom
/
Business
/
Insmed Insider Sold Shares Worth $1,465,680, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Insmed Insider Sold Shares Worth $1,465,680, According to a Recent SEC Filing
Feb 13, 2025 2:29 PM

05:11 PM EST, 02/13/2025 (MT Newswires) -- Sara Bonstein, Chief Financial Officer, on February 11, 2025, sold 18,321 shares in Insmed ( INSM ) for $1,465,680. Following the Form 4 filing with the SEC, Bonstein has control over a total of 137,185 common shares of the company, with 137,185 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1104506/000162828025005465/xslF345X05/wk-form4_1739484553.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Voya Financial Q3 adjusted EPS rises nearly 30% on higher fee income, raises dividend
Voya Financial Q3 adjusted EPS rises nearly 30% on higher fee income, raises dividend
Nov 4, 2025
Overview * Voya Q3 adjusted operating EPS grows nearly 30% yr/yr, driven by segment earnings growth * Company generated over $200 mln excess capital in Q3, reflecting strong financial position * Voya increases quarterly dividend by 4% to $0.47 per share, starting Q4 2025 Outlook * Company confident in long-term growth due to strategic investments and strong balance sheet Result...
Contract logistics provider GXO beats Q3 revenue estimates, reaffirms full-year guidance
Contract logistics provider GXO beats Q3 revenue estimates, reaffirms full-year guidance
Nov 4, 2025
Overview * GXO Q3 revenue rose 8% to $3.4 bln, beating analyst expectations * Adjusted EPS for Q3 met analyst expectations at $0.79 * Adjusted EBITDA for Q3 beat estimates, highlighting strong operational performance Outlook * GXO reaffirms full-year 2025 guidance with organic revenue growth of 3.5% to 6.5% * Company expects adjusted EBITDA of $865 mln to $885 mln...
Corcept Therapeutics misses Q3 revenue expectations, modifies 2025 revenue forecast
Corcept Therapeutics misses Q3 revenue expectations, modifies 2025 revenue forecast
Nov 4, 2025
Overview * Corcept Q3 2025 revenue of $207.6 mln, missed analyst expectations * Net income for Q3 2025 decreased to $19.7 mln from $47.2 mln last year * Company expands oncology programs with new cancer studies Outlook * Corcept modifies 2025 revenue guidance to $800 mln - $850 mln * Company expects to meet increasing demand with new specialty pharmacies...
Assurant Q3 Adjusted Earnings, Revenue Rise
Assurant Q3 Adjusted Earnings, Revenue Rise
Nov 4, 2025
04:43 PM EST, 11/04/2025 (MT Newswires) -- Assurant ( AIZ ) reported Q3 adjusted earnings late Tuesday of $5.73 per diluted share, up from $3.00 a year earlier. Analysts polled by FactSet expected $4.37. Revenue in the three months ended Sept. 30 rose to $3.23 billion from $2.97 billion a year earlier. Analysts surveyed by FactSet expected $3.19 billion. Assurant...
Copyright 2023-2026 - www.financetom.com All Rights Reserved